Phaseline

Companies › NuvOx

NuvOx: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NanO2™ (dodecafluoropentane)
Perfluorocarbon emulsion oxygen delivery agent; increases oxygen delivery to tumors to enh
–Phase 2Glioblastoma Multiforme; Mild Respiratory DistressDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06658535NanO2™ (dodecafluoropentane)Phase 1Mild Respiratory DistressRespiratoryDec 2026
NCT03862430NanO2™ (dodecafluoropentane)Phase 2Glioblastoma MultiformeOncologyJun 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SPARK Biopharma MiNK Therapeutics Nanjing RegeneCore Biotech Guangzhou JOYO Pharma Shanghai Guangsheng Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.